ArticleOxford medical case reports2026
Primary small-cell neuroendocrine carcinoma of the bladder: a very rare histological subtype.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary small cell neuroendocrine carcinoma (SCNC) of the bladder is an exceptionally aggressive malignancy. We report the case of an 80-year-old male, a chronic smoker, presenting with an 8-month history of intermittent total hematuria. Cystoscopy revealed a 72 mm mass infiltrating the bladder dome, posterior, and lateral walls. Histopathological analysis of transurethral resection specimens demonstrated a necrotic diffuse proliferation of monomorphic small cells infiltrating the muscularis propria. Immunohistochemistry showed positivity for synaptophysin, chromogranin A, CD56, and TTF1, whereas GATA3 and p63 were negative. The Ki-67 index exceeded 90%. Systemic staging (cT3bN0M0) confirmed the primary bladder origin. Although multimodal management, including neoadjuvant chemotherapy and radical cystoprostatectomy, was recommended, the patient-initiated chemotherapy but declined surgery. Primary bladder SCNC is a highly invasive entity requiring early diagnosis and multidisciplinary care. The diagnosis is strictly anatomopathological. Differentiating this entity from primary pulmonary small cell carcinoma is a critical challenge, making systemic radiological staging mandatory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.